Assembly Biosciences, Inc. (ASMB)
| Market Cap | 93.33M |
| Revenue (ttm) | 7.29M |
| Net Income (ttm) | -109.02M |
| Shares Out | 47.86M |
| EPS (ttm) | -2.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 855,850 |
| Open | 1.85 |
| Previous Close | 1.89 |
| Day's Range | 1.84 - 1.95 |
| 52-Week Range | 1.84 - 7.02 |
| Beta | 0.66 |
| Analysts | Buy |
| Price Target | 10.00 (+412.8%) |
| Earnings Date | Nov 4, 2021 |
About ASMB
Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, L...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ASMB stock is "Buy." The 12-month stock price forecast is 10.00, which is an increase of 412.82% from the latest price.
News
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...
Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...
Down 30.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Assembly Biosciences (ASMB)
Assembly Biosciences (ASMB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in...
Assembly Biosciences Presents New Data at AASLD The Liver Meeting™ Highlighting the Progress of its HBV Core Inhibito...
Newly selected preclinical core inhibitor candidate, ABI-4334, demonstrates single-digit nanomolar potency against both pgRNA encapsidation and cccDNA formation
Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®
HBV core inhibitor data will be highlighted in one oral and two poster presentations, including one late breaking HBV core inhibitor data will be highlighted in one oral and two poster presentations, in...
Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of...
MENDHAM, N.J., and SOUTH SAN FRANCISCO, Calif.
Assembly Bio Announces October Conference Participation
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...
Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158
--Decision follows observation of elevated alanine transaminase (ALT) levels in Phase 2 study --Company will focus on advancing ongoing triple combination studies and earlier pipeline candidates
Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...
Assembly Biosciences (ASMB) Reports Q2 Loss, Lags Revenue Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 14.06% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B...
Assembly Bio Announces Key Promotions to Leadership Team
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B...
Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nobel Laureate Dr. Michael Houghton Appointed to Assembly Biosciences Board of Directors
Esteemed academic and industry virologist discovered hepatitis C virus (HCV); brings 40+ years of scientific and drug development experience Esteemed academic and industry virologist discovered hepatiti...
Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021
SOUTH SAN FRANCISCO, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...
Assembly Biosciences (ASMB) Reports Q1 Loss, Lags Revenue Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 12.66% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Assembly Biosciences (ASMB) Q1 Earnings Expected to Decline
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Net Current Asset Value Stocks
There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they are convinced they can gain from these kinds of investments after the market has reasses...
Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV Infection
Assembly Biosciences Inc (NASDAQ: ASMB) and Arbutus Biopharma Corp (NASDAQ: ABUS) initiated a Phase 2 trial evaluating the former's vebicorvir (VBR), combined with the latter's AB-729 and standard-of-ca...
Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy
Assembly Biosciences Inc (NASDAQ: ASMB) will not initiate Phase 3 studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive therapy (CST), as the company wants to focus on hepatitis B therapies...
Assembly Biosciences (ASMB) Reports Q4 Loss, Lags Revenue Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of -23.33% and -72.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Vir...
- Prioritizing next generation, more potent core inhibitors, triple combinations with complementary mechanisms of action, and expanding research programs to advance multiple candidates against novel tar...
Will Assembly Biosciences (ASMB) Report Negative Q4 Earnings? What You Should Know
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assembly Bio Announces Upcoming Investor Events
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...
Assembly Biosciences to Wind-Down Microbiome Program
Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio